| Pharmaceutical Information |
| Drug Name |
Tirofiban |
| Drug ID |
BADD_D02228 |
| Description |
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. |
| Indications and Usage |
For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy. |
| Marketing Status |
approved |
| ATC Code |
B01AC17 |
| DrugBank ID |
DB00775
|
| KEGG ID |
D08607
|
| MeSH ID |
D000077466
|
| PubChem ID |
60947
|
| TTD Drug ID |
D0BN9X
|
| NDC Product Code |
68083-145; 25208-001; 25208-002; 55150-430; 55150-429; 25208-901; 25208-902 |
| UNII |
GGX234SI5H
|
| Synonyms |
Tirofiban | N-(Butylsulfonyl)-O-(4-(4-piperidyl)butyl)-L-tyrosine | Aggrastat | Agrastat | MK 383 | MK-383 | L 700462 | L-700462 | L-700,462 | L 700,462 | L700,462 | Tirofiban Hydrochloride | Tirofiban Hydrochloride Monohydrate |
|
| Chemical Information |
| Molecular Formula |
C22H36N2O5S |
| CAS Registry Number |
144494-65-5 |
| SMILES |
CCCCS(=O)(=O)NC(CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
